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Background: Pulmonary Rehabilitation for moderate Chronic Obstructive Pulmonary Disease in primary care could
improve patients’ quality of life.
Methods: This study aimed to assess the efficacy of a 3-month Pulmonary Rehabilitation (PR) program with a
further 9 months of maintenance (RHBM group) compared with both PR for 3 months without further maintenance
(RHB group) and usual care in improving the quality of life of patients with moderate COPD.
We conducted a parallel-group, randomized clinical trial in Majorca primary health care in which 97 patients with
moderate COPD were assigned to the 3 groups. Health outcomes were quality of life, exercise capacity, pulmonary
function and exacerbations.
Results: We found statistically and clinically significant differences in the three groups at 3 months in the emotion
dimension (0.53; 95%CI0.06-1.01) in the usual care group, (0.72; 95%CI0.26-1.18) the RHB group (0.87; 95%CI 0.44-1.30)
and the RHBM group as well as in fatigue (0.47; 95%CI 0.17-0.78) in the RHBM group. After 1 year, these differences
favored the long-term rehabilitation group in the domains of fatigue (0.56; 95%CI 0.22-0.91), mastery (0.79; 95%CI 0.03-
1.55) and emotion (0.75; 95%CI 0.17-1.33). Between-group analysis only showed statistically and clinically significant
differences between the RHB group and control group in the dyspnea dimension (0.79 95%CI 0.05-1.52). No differences
were found for exacerbations, pulmonary function or exercise capacity.
Conclusions: We found that patients with moderate COPD and low level of impairment did not show meaningful
changes in QoL, exercise tolerance, pulmonary function or exacerbation after a one-year, community based
rehabilitation program. However, long-term improvements in the emotional, fatigue and mastery dimensions (within
intervention groups) were identified.
Trial registration: ISRCTN94514482
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Chronic obstructive pulmonary disease (COPD) is a
major, worldwide health problem. In Spain, COPD affects
10.2% of individuals aged 40–80 years and is the fourth
leading cause of death [1]. COPD is a progressive disease,
with chronic and worsening air-flow limitation. In
addition to pathological changes in the lungs, COPD has* Correspondence: miguelroman@ibsalut.caib.es
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reproduction in any medium, provided the orbeen associated with extra-pulmonary manifestations
which contribute to disease severity [2]. The only thera-
peutic measures that have proven effective in avoiding dis-
ease progression are smoking cessation and continuous
home-based oxygen therapy in patients with hypoxemia
[3,4]. Other treatments are associated with control of
symptoms, such as improving dyspnea and patient quality
of life, and avoiding exacerbations and hospitalizations.
Pulmonary rehabilitation (PR) is an evidence-based,
multidisciplinary, comprehensive intervention for patients
with chronic respiratory diseases who are symptomaticLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Pulmonary rehabilitation should be considered for all pa-
tients with chronic respiratory disease who have persistent
symptoms, limited activity, and/or are unable to adjust to
the illness despite otherwise optimal medical management.
Gains can be achieved from pulmonary rehabilitation re-
gardless of age, sex, lung function, or smoking status [5].
This comprehensive intervention has been clearly demon-
strated to reduce dyspnea, improve exercise performance
and health-related quality of life (HRQL), and is a signifi-
cant component in the management of COPD [6]. Fur-
thermore, an emerging literature is beginning to reveal its
effectiveness in reducing health-care costs [7]. PR reduces
hospital admissions and mortality compared with usual
community care (no rehabilitation) in COPD patients fol-
lowing an exacerbation and appears to be a highly effective
and safe intervention. In spite of these clear benefits, only
a small proportion of COPD patients have access to PR
programs. Data from Canada indicates that less than 1.2%
of patients with COPD had access to a PR program per
year [8].
PR can be delivered in a variety of structured programs
that may themselves have an influence on the degree or
duration of long-term benefit [5]. Principles of pulmonary
rehabilitation apply regardless of location and it has been
shown to be effective across various settings including out-
patient and home-care [9-13]. Pulmonary rehabilitation
delivered in a community setting has similar efficacy to
that achieved in a more traditional hospital-based setting.
The potential advantages of community PR programs in-
clude cost-effectiveness, a safe clinical environment and
the availability of trained staff [5]. Some studies show
longer-lasting benefits derived from home-based rather
than hospital-based programs [14] along with evidence that
they provide greater patient comfort and satisfaction [15].
Few studies of a multidisciplinary nature have been per-
formed in the Primary Health Care setting. One integrated
disease-management program (consisting of optimal medi-
cation, reactivation, education, and exacerbation manage-
ment) was developed for primary care patients with COPD
in the Netherlands resulting in improved QoL and de-
creased dyspnea one year after program completion [16].
Another nurse-led, multidisciplinary pulmonary rehabilita-
tion program in primary health care in Sweden found no
significant improvement in functional capacity and QoL
but did find a reduction in exacerbations at 12 months fol-
lowing a 6-week program [17]. The choice of model will
depend on local factors of convenience, existing availability
of resources and incremental costs. Staff characteristics
may be important in achieving optimal outcomes [18].
Other factors associated with PR programs remain un-
certain, including the long-term preservation of benefits
and their optimal duration. Various strategies have been
tried to maintain the benefits of rehabilitation [11,14,15].Continuing rehabilitation for a prolonged period only
seems to confer a small additional benefit and compari-
sons between 18-month and 3-months programs have not
provided greater insight into the matter [19]. There have
been other studies of specific maintenance interventions
after a conventional course of rehabilitation but, as yet,
there is no broad consensus as to their benefit [5].
We compared the efficacy of a 3-month PR program
(education and supervised training) with or without fur-
ther PR maintenance over 9 months in primary health care
centers with that of usual care, with the aim of improving
the quality of life of patients with moderate COPD.
Methods
Design
This study is a parallel-group, randomized clinical trial in-
volving 3 groups of patients with moderate COPD. The
first group received PR for 3 months and rehabilitation
maintenance for 12 months (RHBM group). The second
group received PR for 3 months without further mainten-
ance (RHB group) and the third (control) group received
routine care without rehabilitation (GC group). The study
protocol has been published elsewhere [20].
Selection of patients
Patients were recruited by their family physician from 7
primary care practices in Palma de Mallorca, Spain, from
July 2005 to March 2007. Patients were identified from
both the health center COPD registry and from the results
of spirometry performed at the participating health cen-
ters. Subjects were eligible if they were 35 to 74 years old,
had moderate COPD according to the GOLD criteria and
had post-bronchodilator results on most recent spirom-
etry of FEV1/FVC <0.7, FEV1 values between 50% and
80% [2], and were either smokers or non-smokers. Sub-
jects were excluded if they presented with any musculo-
skeletal conditions that prevented exercising and walking
test assessments, or terminal illness or other severe dis-
ease at the time of enrollment. Identified patients attended
an inclusion visit with a family physician researcher to
check eligibility. During this visit they were asked for writ-
ten informed consent prior to randomization and baseline
measurements. Patient recruitment lasted 12 months.
Intervention
Patients in the two intervention groups participated in a PR
program, delivered in two primary care health centers, con-
sisting of three 60-minute sessions each week for 3 months.
The intervention involved groups of 5–10 patients. The ses-
sions consisted of three types of interventions:
a) Education program. During weeks 1, 6, and 12,
patients received a 45-minute education session on
the anatomy and physiology of the respiratory
Román et al. BMC Family Practice 2013, 14:21 Page 3 of 9
http://www.biomedcentral.com/1471-2296/14/21system, the correct use of inhalers and brief
counseling on smoking cessation.
b)Respiratory Physiotherapy. Each session included a
series of exercises, lasting a total of 15 minutes and
including self-conscious breathing control,
diaphragmatic breathing control, and exercises for
the chest wall and abdominal muscle walls.
c) Low intensity peripheral muscle training. Each
session included abdominal and upper and lower
limb exercises, shoulder and full arm circling,
weight-lifting and other exercises. This training has
been described previously [21] and used in other
clinical trials [22,23]. Each exercise was repeated 8–
10 times over 45 minutes.
Programmed activities were supervised by two physio-
therapists in two primary health centers. They were trained
for 7 days in a hospital PR unit in Barcelona. The physio-
therapist recorded patient attendance at each session.
After completing the 3-month PR program, patients in
the RHBM group attended a weekly-session maintenance
program, including both respiratory physiotherapy and
low intensity peripheral muscle training, until the end of
the program at 12 months. Patients in the RHB group par-
ticipated in routine care with their physician and nurse.
Control group
These patients did not participate in either of the inter-
vention programs; rather, they remained under the routine
care of their general practitioner and nurse throughout.
Randomization & blinding
After the inclusion visit and before baseline evaluation
visit, subjects were randomly assigned to one of the three
groups using a centrally administered, computer-generated
block randomization scheme using blocks of 6 with EPI-
DAT, stratified according to participating site. The case
manager subsequently informed patients of their group al-
location at the end of the baseline visit. The baseline visit
was scheduled when enough patients were recruited to
begin a PR group. Health staff members involved in
follow-up (a psychologist and a nurse) were blinded to pa-
tient assignment.
Measurements
Evaluation visits were scheduled at enrollment, baseline,
and after 3 and 12 months by the study secretary. At each
contact, reasons for not attending PR sessions and evalu-
ation were collected. During the assessment visits, the
Chronic Respiratory Questionnaire was completed by a
psychologist. Subsequently, patients responded to the rest
of the questionnaire and underwent the 6-minute walking
test (6MWT) and spirometry under nurse supervision.Primary outcome variable
The pre-specified primary outcome was the change in
score on the Spanish validated version of the Chronic
Respiratory Questionnaire (CRQ) [24]. Each of the 20
items, in 4 domains (dyspnea, fatigue, emotional function
and mastery or level of control), was graded on a seven-
point Likert scale. An average change in score per item of
0.5 represented minimal, clinically relevant improvement
or worsening [25].Secondary outcome variables
Pulmonary function tests included forced spirometry and
reversibility test with salbutamol. According to ERS-ATS
recommendations, we used a Datospir 120 spirometer and
measured FVC, FEV1 and FEV1/FVC, with results com-
pared to Roca-Separ Spanish-specific reference values [26].
Exercise tolerance was assessed through the 6MWT.
Two tests were performed per session, with a rest of at
least 30 minutes between tests and the best result was used
for each patient [27]. During the test, oxygen saturation
and heart rate were monitored using a portable saturation
monitor. Tests were stopped if subjects experienced chest
pain, mental confusion, intolerable dyspnea or oxygen sat-
uration <90. The Borg dyspnea scale was completed before
and after each 6MWT.
Any hospital admissions and visits to family physician
due to COPD exacerbations. Exacerbation was defined as
episodes of either dyspnea or dry or productive cough,
whether sputum was purulent or not, which were treated
with oral corticosteroids and/or antibiotics. Also treat-
ments with antibiotics or corticosteroids. These variables
were recorded at baseline and final visit. At the baseline
visit, patients were asked about episodes during the
12 months before enrollment and, at the final visit, about
episodes suffered during follow-up. This information was
confirmed by a nurse researcher review of primary care
and hospital medical records.
Others variables included group allocation; demographic
variables such as sex, age, smoking habits and packs/year;
treatments for COPD; and dyspnea, as measured by the
Medical Research Council (MRC) [28].Sample size
Sample size calculation was based on the difference in
expected improvement in quality of life between the inter-
vention RHBM group and the control group. This im-
provement was defined as the difference between the
mean global score on the CRQ scale at baseline and post-
rehabilitation. Sample size was calculated with ENE pro-
gram version 2.1, Glaxo SA. A difference of 10 (0.5 per
item for 20 items) was recognized as the minimum, clinic-
ally relevant difference. With an α level of 0.05, a 1-beta of
0.8 and a standard deviation of 17 [22], and anticipating a
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subjects to each group.
Statistical analysis
All statistical analyses were carried out on a modified
intention-to-treat basis with SPSS v.14. Some patients had
difficulty in keeping evaluation appointments. Missing
values at evaluation visits were substituted with basal
values. However, the numbers of hospital admissions and
exacerbations, and the usual treatment of patients, were
not replaced by basal values and were scored as missing
values.
To reduce bias caused by large withdrawal rate, we did
sensitivity analysis. We performed per-protocol analysis,
analysis with baseline values for missing data and analysis
with multiple imputation for missing data. The three ana-
lyses gave the same results. Reported results are for ana-
lysis with baseline values replacing missing data.
The chi-square test was used to compare between-
group smoking habits and health services utilization for
COPD exacerbation. Comparisons of normal variables
among the three groups were assessed by ANOVA to-
gether with the Tukey post-hoc test.
For the primary outcomes (Chronic Respiratory Ques-
tionnaire subscale score, pulmonary function and 6-minute
walking) we calculated within-group differences from base-
line and 95%CI (with a fixed-effects regression model)
adjusting for baseline scores using the treatment group as
a predictor. Separate regression analyses predicted treat-
ment differences at 3-month and 12-month evaluations.
We conducted generalized linear models analyses (GLM)
to estimate adjusted treatment differences and within-
group and between-group differences, and the Bonferroni
test to compare between-group differences. For the sec-
ondary outcomes, we used Poisson regression to analyze
exacerbation rates requiring hospitalization and negative
binomial to estimate the other variables covering health-
care utilization data. All the analysis was two-tailed, with
an alpha level of 5%.
The study received the approval of the Baleares Ethics
Committee and the Majorca Primary Care Research
Committee.
Results
We identified 97 patients who met all inclusion criteria
and none of the exclusion criteria. All agreed to partici-
pate. Allocation resulted in 32 subjects randomized to the
control group, 33 to the RHB group and 32 to the RHBM
group. For some patients, the lag time from enrollment to
basal evaluation was longer than expected because basal
evaluations did not start until a minimum number of sub-
jects were gathered for a rehabilitation group. The mean
interval-time for each group was: 87 days for the control
group, 110 days for the RHB group and 94 days for theRHBM group (Table 1). No significant between-group dif-
ferences were found.
During that period some patients were lost and did not
attend basal evaluation. Finally, 23 patients were included
in the control group, 22 in the RHB group and 26 in the
RHBM group; these patients were included in our analysis.
Figure 1 summarizes the patient flow and follow-up evalu-
ation. Some subjects withdrew between randomization
and baseline evaluation and others were temporarily lost
to follow-up, but were evaluated after 12 months. Subjects
in the RHBM group attended an average of 25 sessions
each, or 69.4% of the planned sessions during the first
three months, and an average of 21 during the mainten-
ance period, that is, 58.3% of the planned sessions. Sub-
jects in the RHB group attended an average of 13 sessions,
or 36.1% of the sessions over the 3 month period.
Patients’ socio-demographic characteristics included in
the analysis showed similar distributions among the three
groups at baseline, with none of the parameters showing
statistically significant differences (Table 1). Of the pa-
tients who withdrew, 82.5% were men with an average age
of 62.1 (SD = 15.9) years and a FEV1 of 60% (SD = 10.6).
Disease severity and functional capacity, as well as CRQ
scores, were also well balanced among the distinct inter-
vention groups.
Primary outcome
Within-group comparison (Table 2) showed significant
and clinically relevant improvements in CRQ emotion
scores at 3 months in the two rehabilitation groups. These
effects were maintained at 12 months in the RHBM group.
Also, significant and clinically relevant improvements
were observed in the RHBM group at 3 and 12 month
follow-up for fatigue. However, in the mastery dimension,
the improvement only reached significant and clinically
relevant differences at 12 months in the RHBM group.
Between-group comparisons included in Table 3 show sig-
nificant differences between the control and RHM group
at 3 months for dyspnea scores. Between-group changes
for other CRQ dimensions scores were not significant and
clinically unimportant. Per protocol analysis and multiple
imputation of missing values generated the same results.
Secondary outcomes
All 3 groups maintained pulmonary function, with no
relevant significant changes, at both time points (Table 2
and Table 3). No differences within or between groups
were observed in the 6-MWT. As shown in Table 4, no
statistically significant differences were noted in health
care outcomes.
Discussion
Our study evaluated the long-term effects of a PR pro-
gram in a community primary care setting with moderate







Number of subjects 23 (32.4) 22 (31) 26 (36.6)
Sex
Female 4 (17.4) 4 (18.2) 5 (19.2)
Male 19 (82.6) 18 (81.8) 21 (80.8)
Working
Yes 5 (22.7) 6 (27.3) 7 (26.9)
Smoking habits
Smoker 8 (34.8) 7 (31.8) 9 (34.6)
Never smoked 2 (8.7) 0 (0.0) 1 (3.8)
Ex-smoker 13 (56.5) 15 (68.2) 16 (61.5)
MRCs dyspnea score category
0 11 (47.8) 7 (31.8) 4 (15.4)
1 11 (47.8) 11 (50.0) 17 (65.4)
2 1 (4.3) 2 (9.1) 5 (19.2)
3 0 (0.0) 1 (4.5) 0 (0.0)
4 0 (0.0) 1 (4.5) 0 (0.0)
Lag time enrolment to basal/
















































































COPD exacerbation visit to
family physician
Yes n (%) 12 (52.2) 9 (40.9) 7 (28)
















l = litres; m =meters; CI = Confidence Interval; χ2 for categorical variables and
ANOVA for continuous variables.
No significant between-group differences were found for any of the variables.
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showed a significant improvement in the emotional di-
mension after 3 months. This improvement was only
maintained in the group that completed the one-year
maintenance PR program but not in the 3-month inter-
vention group. Benefits in the fatigue and mastery dimen-
sions also observed after one year of program maintenance
were not achieved in the other 2 comparison groups. Lack
of improvement in exercise tolerance and overall QoL rat-
ings between groups did not allow accurate determination
of PR short- and long-term effectiveness.
Previous studies reported that emotional improvement
after the intervention was not maintained after discon-
tinuation or not even after complete PR maintenance pro-
grams [29,30], being the first deteriorated QoL dimension.
Our results are in line with those reported by Moullec and
Chavannes where PR maintenance strategies carried out
in the community were associated with long-term im-
provements in QoL [16,31]. Emotional benefits were ob-
served in both PR groups at 3 months and persisted in the
group that continued pulmonary rehabilitation together
with improvements in two domains that include socio-
psychological components. One explanation could be the
beneficial results of mixing with individuals with similar
problems and sharing negative experiences with disease.
The social support of other COPD patients and the long-
term attention of a physiotherapist would promote a
reduction in emotional reactions and development of
adapted behaviors [31].
Otherwise, between-group findings are not in line with
the results of Lacasse et al. meta-analysis [6], as we were
not able to find a consistent improvement in any quality-
of-life dimension. The patient’s QoL was generally good at
baseline and therefore had little scope to show large
improvements through low intensity PR activities. Only
dyspnea improved significantly after 3 months of PR in
the RHB group compared to controls. This results could
appear paradoxical given the very low attendance rate
(36%) in this group; much lower than the RHBM group
(69%). Patients showed a low baseline level of dyspnea in
the MRC scale and high exercise capacity in the 6MWT.
In fact, 22 patients had dyspnea with intense exercise
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Figure 1 Study design.
Table 2 Chronic respiratory questionnaire subscale score, pulmonary function and 6-minute walking test differences
from baseline to 3 and 12 months
Control n = 23 RHB n = 22 RHBM n = 26
3 months 12 months 3 months 12 months 3 months 12 months
CRQ
Fatigue 0.4 (−0.05-0.7) 0.2 (−0.1-0.6) 0.03 (−0.3-0.4) 0.3 (−0.1-0.6) 0.5 (0.2-0.8)* 0.56 (0.2-0.9)*
Mastery −0.6 (−1.1- - 0.1)* 0.3 (−0.5-1.2) −1.01 (−1.5- -0.5)* 0.01 (−0.8-0.8) −0.3 (−0.8-0.15) 0.79 (0.03-1.5)*
Dyspnea −0.5(−0.9- - 0.1)* −0.4 (−0. 8–0.01) 0.3 (−0.1-0.7) 0.07 (−0.3-0.5) −0.2 (−0.6-0.2) −0.23 (−0.6-0.1)
Emotion 0.5 (0.06-1.01)* 0.00 (−0.6-0.6) 0.7 (0. 3–1.2)* 0.5 (−0.13-1.11) 0.9 (0.5-1.3)* 0.7 (0.2-1.3)*
FVC (l) −1.5 (−4.7-1.7) 1.42 (−2.4-5.3) 0.5 (−2.8-3.9) 3.0 (−1.04-7.05) −2.4 (−5.5-0.6) −0.9 (−4.7-2.7)
FEV1 (l) 0.8 (−2.5-4.2) −0.22 (−1.3-0.9) −0.03 (−3.5-3.5) −0.1 (−1.3-0.9) −2.1 (−5.3-1.1) −1.2 (−2.2- - 0.1)*
FEV1/FVC 0.8 (−1.9-3.6) 3.03 (0.6-5.5)* −0.5 (−3.3-2.2) −1.8 (−4.3-0.6) −0.3 (−2.8-2.2) −0.08 (−2.3-2.1)
Walking test (m) 27.3 (4.4-50.3)* 33.2 (8.2-58.3)* 0.9 (−22.6-24.3) 20.2 (−5.3-45.8) 19.5 (−2.07-41.1) 19.7 (−3.8-43.3)
Within-group differences from baseline (95%CI).
*P < 0.05. Values are means and 95%CI’s. A difference greater than 0.5 (improvement) or greater than −0.5 ( deterioration) in CRQ scores, is considered
clinically important.
m =meters.
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Table 3 Chronic respiratory questionnaire subscale score, pulmonary function and 6-minute walking test differences
from baseline to 3 and 12 months
3 months 12 months
RHB-Control n = 23 RHBM-Control n = 22 RHBM-RHB n = 26 RHB-Control n = 23 RHBM-Control n = 22 RHBM-RHB n = 26
CRQ
Fatigue −0.3 (−0.9-0.2) 0.09 (−0.5-0.6) 0.4 (−0.1-0.9) 0.02 (−0.6-0.6) 0.3 (−0.3-0.9) 0.3 (−0.3-0.9)
Mastery −0.4 (−1.3-0.5) 0.3 (−0.5-1.1) 0.7 (−0.1-1.5) −0.3 (−1.8-1.1) 0.4 (−0.9-1.8) 0.8 (−0.6-2.1)
Dyspnea 0.8 (0.05-1.5)* 0.3 (−0.4-0.9) −0.5 (−1.2-0.2) 0.5 (−0.2-1.1) 0.1 (−0.5-0.8) −0.3 (−0.9-0.3)
Emotion 0.2 (−0.6-0.9) 0.3 (−0.5-1.1) 0.1 (−0.6-0.9) 0.5 (−0.6-1.6) 0.7 (−0.3-1,8) 0.3 (−0.8-1.3)
FVC (l) 2.05 (−3.7-7.8) −0.9 (−6.4-4.5) −2.9 (−8.6-2.6) 1.6 (−5.2-8.4) −2.4 (−8.9-4.1) −3.9 (−10.7-2.7)
FEV1 (l) −0.9 (−6.8-5.04) −2.9 (−8.6-2.7) −2.05 (−7.8-3.7) 0.07 (−1.8-1.9) −0.9 (−2.8-0.9) −1.04 (−2.9-0.8)
FEV1/FVC −1.4 (−6.1-3.4) −1.12 (−5.7-3.4) 0.2 (−4.3-4.8) −4.8 (−9.1- -0.6)* −3.1 (−7.2-0.9) 1.7 (−2.3-5.8)
Walking test (m) −26.4 (−66.5-13.6) −7.8 (−46.3-30.7) 18.6 (−20.3-57.8) −12.9 (−56.7-30.7) −13.5 (−55.5-28.5) −0.5 (−43.02-41.9)
*P < 0.05. Values are means and 95%CI’s. A difference greater than 0.5 (improvement) or greater than −0.5 (deterioration) in CRQ scores, is considered
clinically important.
m =meters.
Between-group differences (RHB group minus control group, RHBM minus control, RHBM-RHB).
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had a MRC scale score >1.
In common with most PR studies conducted on
COPD patients, we found no improvements in pulmon-
ary function parameters [10,21,32]. Our patients follow-
ing the rehabilitation program did not show significant
improvements in exercise capacity in contrast to those
described in a previous meta-analysis [6], and in a more
recent study [33] where PR, including a much more in-
tensive exercise such as endurance training, was highly
effective in improving the exercise capacity of patients
with COPD. Our RHB program included low intensity
peripheral muscle training but did not have any endur-
ance training which could explain this lack of effect. As





Yes n (%) 3 (15.8) 5 (22.7) 3 (12.5)






COPD exacerbation visit to
family physician
Yes n (%) 9 (42.8) 7 (35) 7 (30.3)






COPD treatment with antibiotics
or corticoids
Yes n (%) 6 (33.4) 5 (26.3) 4 (20)






No significant between-group differences were found for any of the variables.exercise capacity with a mean walking distance between
436 and 466 meters while the Italian study baseline
mean distance was around 300 meters [33].
By selecting patients with low basal symptoms, the ef-
fectiveness of the intervention can be limited as described
by others [17]. These findings suggest that the greatest
room for improvement in primary care patients can be
expected in those with tangible dyspnea and impaired
health status (MRC score > 2 and/or CCQ score >1) across
all GOLD stages [16,34].
We found that the proportions of individuals with some
exacerbation episodes were similar in the three groups, in
agreement with previous studies [35,36], while a recent PR
primary care program found a reduction in exacerbation
rate after a community PR program [17].
Most PR programs are based at hospitals or at home
[10-12,14,33,37]. The intervention we evaluated was de-
veloped in primary care centers, with the existing resources
of those health centers. In so doing, we attempted to show
that this intervention was feasible in a setting where PR is
not a regular service but highly accessible for patients. Few
PR integrated community programs have been developed
with primary care resources and though they found bene-
fits, the results are not conclusive [16,17]. Low patient
compliance with the intervention indicates the need for a
more integrated approach in order to involve patients as
active partners in their treatment process and achieve posi-
tive results in behavior modification [31,38].
Our study showed persistent within-group improve-
ments in QoL after only a 1-year maintenance program,
with no similar effects in the 3-month program group.
At this moment it is not known how long these pro-
grams should take and how they might influence behav-
ior [38] or whether alternative management such as an
action-plan or self-management strategies could result
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believed that longer programs yield more durable train-
ing effects but the majority of existing studies looking
for long-term results, such as ours, have shown small
improvements which may not always be possible to rep-
licate [11,15-17,19,23,32,34].
Limitations
One important limitation arises from the fact that we were
not able to recruit the sample size required. Even with ac-
tive review of included-centers’ registers and COPD
patients records, fewer patients than expected were identi-
fied. This is consistent with the results of other studies
showing COPD under-reporting [40] and the difficulties
of recruiting patients with COPD to a PR trial. This
affected the power of the study to identify significant
changes in the PR groups and led to negative results.
The high rate of withdrawal was also an obstacle to
obtaining fair results. Of the patients initially included,
almost 50% withdrew after randomization and the re-
mainder showed moderate adherence to PR sessions.
These two limitations reduced the power of this study to
identify PR benefits. The characteristics of patients lost
after initial evaluation did not differ significantly among
the three randomized groups, indicating that loss to
follow-up did not alter our final results.
In analyzing the factors related to non-adherence, we
found that one of the primary health care centers was
located far from the city center thus limiting accessibility
to patients living far away. Low adherence during the
second year of PR in our first cohort study resulted in a
deviation from protocol, which was designed to evaluate
the long-term (24-month) effect of PR maintenance.
Patient withdrawal due to morbidity and mortality also
had a negative influence on our final sample. Most studies
analyzing similar rehabilitation programs in COPD pa-
tients have also shown considerable loss to follow-up, even
higher than ours [15,41,42]. In addition, the PR provided
in groups of patients probably made it more difficult to
adapt to the timetable than if it were performed individu-
ally and, as such, influenced adherence to PR sessions.
Conclusions
We found that patients with moderate COPD and low
level of impairment did not show meaningful changes in
QoL, exercise tolerance, pulmonary function or exacer-
bation after a one-year, community-based rehabilitation
program. However, long-term improvements in the emo-
tional, fatigue and mastery dimensions were identified.
COPD is a disease in which most interventions, including
pharmacological interventions, produce low levels of ben-
efits that do not lead to quality of life improvements and a
reduction in exacerbations. The selection of patients for
community-based rehabilitation programs should bebased on level of impairment and regular symptoms. The
maintenance of benefits is highest in the group which
completed the entire 12-month intervention although the
long-term effects of PR programs is still unknown and
more studies are needed to establish the optimum dur-
ation and nature of maintenance programs. These benefits
are less evident in patients with moderate COPD.
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